CTOs on the Move

BrainStorm Cell

www.brainstorm-cell.com

 
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

BrainStorm Cell raised $16M on 07/21/2017

Similar Companies

PharMEDium Healthcare Corporation

PharMEDium is an organization that has established an outstanding reputation for quality and customer service in the healthcare marketplace. Credit for this goes to everyone in the organization. We hope you, too, will find satisfaction and take pride in

RxHub

RxHub LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ChemBridge

ChemBridge Corporation is a privately held US company founded in Chicago in 1993 and relocated to San Diego in 1997. ChemBridge has European offices in the UK, a marketing agency in Japan, and operates a large, state-of-the-art offshore chemistry

Connections Behavior Planning & Intervention

ABA Therapy for children with ASD, EBD, & developmental disabilities. We serve King County, WA including Kent, Renton, Seattle, Kirkland, Redmond, & more.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.